section name header

Pronunciation ⬇

o-ma-LIZ-ue-mab

Classifications ⬆ ⬇

Therapeutic Classification: antiasthmatics

Pharmacologic Classification: monoclonal antibodies

Indications ⬆ ⬇

REMS


Action ⬆ ⬇

  • Inhibits binding of IgE to receptors on mast cells and eosinophils, preventing the release of mediators of the allergic response. Also lowers amount of IgE and decreases amount of IgE receptors on basophils.
Therapeutic effects:
  • Decreased incidence of exacerbations of asthma.
  • Decreased severity of itching and quantity of hives.
  • Reduction of Type I allergic reactions, including anaphylaxis.
  • Decreased size of nasal polyps and decreased severity of nasal congestion.

Pharmacokinetics ⬆ ⬇

Absorption: 62% absorbed slowly from SUBQ sites.

Distribution: Unknown.

Metabolism/Excretion: Degraded similarly to IgG via binding degradation, reticuloendothelial system and the liver.

Half-Life: 26 days.

Time/Action Profile ⬆ ⬇

(effects on IgE levels)

ROUTEONSETPEAKDURATION
SUBQwithin 1 hrunknownup to 1 yr



Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

Interactions ⬆ ⬇

Drug-drug:

Route/Dosage ⬆ ⬇

Asthma

Chronic Idiopathic Urticaria

IgE-Mediated Food Allergy

Chronic Rhinosinusitis with Nasal Polyps

Availability ⬆ ⬇

Assessment ⬆ ⬇

Lab Test Considerations:

Implementation ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

US Brand Names ⬆

Xolair